Achillion Pharmaceuticals Inc. (ACHN) Financials N

Achillion Pharmaceuticals Inc. (ACHN) Financials Nov 20, 2014, 5:14 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Achillion Pharmaceuticals Inc.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue (294,000) 2.44M 247,000 2.61M 0
Cost of Goods Sold (COGS) incl. D&A 3.33M 3.27M 3.44M - 399,000
COGS excluding D&A 2.35M 2.65M 3.11M - 0
Depreciation & Amortization Expense 987,000 615,000 327,000 408,000 399,000
Depreciation 936,000 571,000 317,000 402,000 399,000
Amortization of Intangibles - - 0 6,000 0
Gross Income (3.63M) (829,000) (3.19M) - (399,000)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 21.64M 24.47M 41.16M 50.05M 59.08M
Research & Development 18.42M 20.53M 35.44M 39.55M 46.74M
Other SG&A 3.22M 3.94M 5.72M 10.49M 12.34M
Other Operating Expense 0 0 0 0 0
Unusual Expense 274,000 0 0 0 0
EBIT after Unusual Expense (274,000) 0 0 0 0
Non Operating Income/Expense 0 0 0 0 0
Non-Operating Interest Income 172,000 101,000 186,000 234,000 582,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 564,000 284,000 45,000 68,000 52,000
Gross Interest Expense 564,000 284,000 45,000 68,000 52,000
Interest Capitalized 0 0 0 0 0
Pretax Income (25.93M) (25.48M) (44.21M) (47.68M) (58.95M)
Income Tax 0 0 0 (554,000) 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income (25.93M) (25.48M) (44.21M) (47.13M) (58.95M)
Minority Interest Expense 0 0 0 0 0
Net Income (25.93M) (25.48M) (44.21M) (47.13M) (58.95M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (25.93M) (25.48M) (44.21M) (47.13M) (58.95M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (25.93M) (25.48M) (44.21M) (47.13M) (58.95M)
EPS (Basic) (0.98) (0.57) (0.69) (0.64) (0.63)
Basic Shares Outstanding 26.54M 45.08M 64.25M 73.97M 93.98M
EPS (Diluted) (0.98) (0.57) (0.69) (0.64) (0.63)
Diluted Shares Outstanding 26.54M 45.08M 64.25M 73.97M 93.98M
EBITDA (24.28M) (24.68M) (44.02M) (47.44M) (59.08M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.